文 献1）Larson RA, Drunker BJ, Guilhot F, O'Brien SG, Riviere GJ, Krahnke T, et al. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood 2008; 111, 4022-8.2）Noda S, Otsuji T, Baba M, Yoshida T, Kageyama S, Okamoto K, et al. Assessment of sunitinib-induced toxicities and clinical outcomes based on Therapeutic Drug Monitoring of sunitinib for patients with renal cell carcinoma. Clin Genitourin Cancer 2015; 13: 350-8.3）Tomita Y, Tatsugami K, Nakaigawa N, Osawa T, Oya M, Kanayama H, et al. Cabozantinib in advanced renal cell carcinoma: A phaseⅡ, open-label, single-arm study of Japanese patients. Int J Urol 2020; 27: 952-7.4）Cerbone L, Combarel D, Geraud A, Auclin E, Foulon S, Alves CS, et al. Association of cabozantinib pharmacokinetics, progression and toxicity in metastatic renal cell carcinoma patients: results from a pharmacokinetics/pharmacodynamics study. ESMO Open 2021; 6: 100312.5）Castellano D, Maroto JP, Benzaghou F, Taguieva N, Nguyen L, Clary DO, et al. Exposure-response modeling of cabozantinib in patients with renal cell carcinoma: Implications for patient care. Cancer Treat Rev 2020; 89: 102062.6）Krens SD, Erp NP, Groenland SL, Moes DJ, Mulder SF, Desar IM, et al. Exposure-response analysis of cabozantinib in patients with metastatic renal cell cancer. BMC Cancer 2022; 22: 228.7）Lin QH, Li YH, Lu XR, Wang R, Pang NH, Xu RA, et al. Characterization of genetic variation in CYP3A4 on the metabolism of cabozantinib in vitro. Chem Res Toxicol 2019; 32: 1583-90.27
元のページ ../index.html#41